PPIDT00121
Drug Information
| Name | Oritavancin |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB04911 |
| Type | small molecule |
| Indication | Oritavancin is indicated for the treatment of adult patients with acute bacterial skin and skin structure (including subcutaneous) infection. It is used for confirmed/suspected infections with designated and susceptible gram-positive organisms.[L8492] There are two preparations of oritavancin; the 400 mg dose that is administered over 3 hours, and the 1200 mg dose administered over 1 hour. Both are indicated for susceptible gram-positive skin and skin structure infections in adults.[L8492,L32629] As antimicrobial susceptibility patterns are geographically distinct, local antibiograms should be consulted to ensure adequate coverage of relevant pathogens prior to use. |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, lyophilized, for solution | Intravenous |
1200 mg/40mL
|
| Injection, powder, lyophilized, for solution | Intravenous |
400 mg/1
|
| Injection, powder, for solution | Intravenous |
1200 mg
|
| Injection, powder, for solution | Intravenous |
400 MG
|
Target Information
| Role | Uniprot_ID | Gene_Name | Entity_Name | Organism | Actions | Internal link |
|---|---|---|---|---|---|---|
| target | P0AC13 | folP | Dihydropteroate synthase | Escherichia coli (strain K12) | inhibitor | Link |
| enzyme | P08684 | CYP3A4 | Cytochrome P450 3A4 | Homo sapiens | inhibitor|inducer | Link |
| enzyme | P10635 | CYP2D6 | Cytochrome P450 2D6 | Homo sapiens | inhibitor|inducer | Link |
| enzyme | P11712 | CYP2C9 | Cytochrome P450 2C9 | Homo sapiens | inhibitor | Link |
| enzyme | P33261 | CYP2C19 | Cytochrome P450 2C19 | Homo sapiens | inhibitor | Link |
| carrier | P02768 | ALB | Albumin | Homo sapiens | binder | Link |